Stock LBPH LONGBOARD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
19.72 USD +2.44% Intraday chart for Longboard Pharmaceuticals, Inc. +13.07% +227.03%
03-26 Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI
03-18 Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Longboard Pharmaceuticals Closes $242 Million Public Offering
Longboard Pharmaceuticals Prices $210 Million Stock Offering
Longboard Pharmaceuticals Launching Share Offering
Sector Update: Health Care Stocks Gain Late Afternoon
Longboard Pharmaceuticals Shares Surge After Positive Topline Results for Seizures Treatment
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Top Midday Gainers
Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin in Participants with Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Longboard Completes Enrollment in Study of LP352 for Treatment of Developmental, Epileptic Encephalopathies
Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Longboard Pharmaceuticals Prices Offering at $4 Per Share
Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. Executes into Second Amendment to That Certain License Agreement
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LBPH Stock
  4. News Longboard Pharmaceuticals, Inc.
  5. Other languages